Tirzepatide (Mounjaro): approved dosage
Not a recommendation, not treatment guidance. This page shows only the dosing in the official product information, with sources. The dose is always decided by the doctor who prescribes the medicine. Fimea warns against using injectable peptides bought online: Fimea warning.
Source of the dosing: Mounjaro (tirzepatide), EMA summary of product characteristics (EMA), date of the text 21 Sep 2026 [1]official
Tirzepatide is authorised in the EU as Mounjaro (tirzepatide), with two indications: insufficiently controlled type 2 diabetes in adults and children aged 10 and over, and weight management in adults [1]official.
Mounjaro (tirzepatide) is injected under the skin once a week, and the doses in the table come from the summary of product characteristics approved by the European Medicines Agency (EMA) [1]official.
Dosing in the product information
| Product and step | Indication | Dose | Frequency | Duration | Source and level |
|---|---|---|---|---|---|
| Mounjaro (tirzepatide), start | Type 2 diabetes (adults and children aged 10 and over) and weight management (adults) | 2.5 mg under the skin | Once a week | 4 weeks | [1]official |
| Mounjaro (tirzepatide), escalation | Type 2 diabetes (adults and children aged 10 and over) and weight management (adults) | 5 mg under the skin; if needed, increases in 2.5 mg steps | Once a week | At least 4 weeks on each dose | [1]official |
| Mounjaro (tirzepatide), maintenance in adults | Adults, both indications | 5 mg, 10 mg or 15 mg under the skin (maximum 15 mg) | Once a week | Not set in the product information | [1]official |
| Mounjaro (tirzepatide), maintenance in children and adolescents | Type 2 diabetes, ages 10-17 | 5 mg or 10 mg under the skin (maximum 10 mg) | Once a week | Not set in the product information | [1]official |
Evidence levels: official = official product information · A = randomised human trial or meta-analysis · B = observational human study or case series · C = animal study · D = cell or laboratory study · E = not peer-reviewed
Notes
The same start and escalation apply to both indications; the maximum dose is 10 mg in children and adolescents and 15 mg in adults [1]official.
What points the other way or is uncertain
Gastrointestinal effects rise with the dose: in placebo-controlled type 2 diabetes trials they occurred in 37.1% (5 mg), 39.6% (10 mg) and 43.6% (15 mg) versus 20.4% on placebo, and 3.0%, 5.4% and 6.6% stopped treatment because of them (placebo 0.4%) [1]official.
When tirzepatide was switched to placebo after 36 weeks, weight rose by 14.0% on average over the next 52 weeks, while it fell by 5.5% in those who continued (SURMOUNT-4, 670 participants) [2]A.
- Tirzepatide (Mounjaro): the full substance page
- Tirzepatide (Mounjaro): calculator not for approved medicine
- Are peptides legal in Finland?
- All dose pages and calculators
Read the research yourself: sources
- European Medicines Agency. Mounjaro (tirzepatide): EPAR product information, Annex I summary of product characteristics. Last updated 21 Sep 2026, read 12 Oct 2026. EMA
- Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. PMID 38078870
- Horn DB, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2026;407(10545):2305-2318. PMID 42119587
The summary of product characteristics carries no revision date. The date shown is the last update of the product information on the EMA medicine page (21 Sep 2026). Checked on 12 Oct 2026.
Content is general information about research, not medical advice. If you have symptoms, contact a healthcare professional.